Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media

V. N. Gan, H. Kusmiesz, S. Shelton, J. D. Nelson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

One hundred five infants and children with acute otitis media were randomized to therapy with loracarbef, an experimental carbacephem antibiotic, or amoxicillin-clavulanate (Augmentin), an approved drug for this disease. Ninety-two were evaluable (46 in each group). Middle ear fluid samples obtained for culture before therapy grew Haemophilus spp. in 30% of cases, pneumococci in 29% of cases, and Moraxella catarrhalis in 15% of cases. β-Lactamase-producing bacteria were found in 37% of patients. Clinical failure occurred in four loracarbef-treated patients and one amoxicillin-clavulanate-treated patient (P = 0.361). Recurrence of acute otitis media was more common in the 2 to 3 weeks after loracarbef treatment (eight patients) than it was after amoxicillin-clavulanate therapy (three patients), but not significantly so (P = 0.197). Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0.052). Gastrointestinal side effects occurred in 13 loracarbef-treated and 21 amoxicillin-clavulanate-treated patients (P = 0.13). Diaper rash was more common with amoxicillin-clavulanate (22 patients) than with loracarbef (10 patients; P = 0.016). Satisfactory results were achieved with both antibiotics, and adverse effects, although common, were minor.

Original languageEnglish (US)
Pages (from-to)967-971
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume35
Issue number5
StatePublished - 1991

Fingerprint

loracarbef
Clavulanic Acid
Amoxicillin
Otitis Media
Diaper Rash
Anti-Bacterial Agents
Haemophilus
Moraxella (Branhamella) catarrhalis
Recurrence
Amoxicillin-Potassium Clavulanate Combination
Middle Ear
Therapeutics
Streptococcus pneumoniae

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media. / Gan, V. N.; Kusmiesz, H.; Shelton, S.; Nelson, J. D.

In: Antimicrobial Agents and Chemotherapy, Vol. 35, No. 5, 1991, p. 967-971.

Research output: Contribution to journalArticle

@article{e488d5f778e64474b60dff8052f18c48,
title = "Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media",
abstract = "One hundred five infants and children with acute otitis media were randomized to therapy with loracarbef, an experimental carbacephem antibiotic, or amoxicillin-clavulanate (Augmentin), an approved drug for this disease. Ninety-two were evaluable (46 in each group). Middle ear fluid samples obtained for culture before therapy grew Haemophilus spp. in 30{\%} of cases, pneumococci in 29{\%} of cases, and Moraxella catarrhalis in 15{\%} of cases. β-Lactamase-producing bacteria were found in 37{\%} of patients. Clinical failure occurred in four loracarbef-treated patients and one amoxicillin-clavulanate-treated patient (P = 0.361). Recurrence of acute otitis media was more common in the 2 to 3 weeks after loracarbef treatment (eight patients) than it was after amoxicillin-clavulanate therapy (three patients), but not significantly so (P = 0.197). Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0.052). Gastrointestinal side effects occurred in 13 loracarbef-treated and 21 amoxicillin-clavulanate-treated patients (P = 0.13). Diaper rash was more common with amoxicillin-clavulanate (22 patients) than with loracarbef (10 patients; P = 0.016). Satisfactory results were achieved with both antibiotics, and adverse effects, although common, were minor.",
author = "Gan, {V. N.} and H. Kusmiesz and S. Shelton and Nelson, {J. D.}",
year = "1991",
language = "English (US)",
volume = "35",
pages = "967--971",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media

AU - Gan, V. N.

AU - Kusmiesz, H.

AU - Shelton, S.

AU - Nelson, J. D.

PY - 1991

Y1 - 1991

N2 - One hundred five infants and children with acute otitis media were randomized to therapy with loracarbef, an experimental carbacephem antibiotic, or amoxicillin-clavulanate (Augmentin), an approved drug for this disease. Ninety-two were evaluable (46 in each group). Middle ear fluid samples obtained for culture before therapy grew Haemophilus spp. in 30% of cases, pneumococci in 29% of cases, and Moraxella catarrhalis in 15% of cases. β-Lactamase-producing bacteria were found in 37% of patients. Clinical failure occurred in four loracarbef-treated patients and one amoxicillin-clavulanate-treated patient (P = 0.361). Recurrence of acute otitis media was more common in the 2 to 3 weeks after loracarbef treatment (eight patients) than it was after amoxicillin-clavulanate therapy (three patients), but not significantly so (P = 0.197). Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0.052). Gastrointestinal side effects occurred in 13 loracarbef-treated and 21 amoxicillin-clavulanate-treated patients (P = 0.13). Diaper rash was more common with amoxicillin-clavulanate (22 patients) than with loracarbef (10 patients; P = 0.016). Satisfactory results were achieved with both antibiotics, and adverse effects, although common, were minor.

AB - One hundred five infants and children with acute otitis media were randomized to therapy with loracarbef, an experimental carbacephem antibiotic, or amoxicillin-clavulanate (Augmentin), an approved drug for this disease. Ninety-two were evaluable (46 in each group). Middle ear fluid samples obtained for culture before therapy grew Haemophilus spp. in 30% of cases, pneumococci in 29% of cases, and Moraxella catarrhalis in 15% of cases. β-Lactamase-producing bacteria were found in 37% of patients. Clinical failure occurred in four loracarbef-treated patients and one amoxicillin-clavulanate-treated patient (P = 0.361). Recurrence of acute otitis media was more common in the 2 to 3 weeks after loracarbef treatment (eight patients) than it was after amoxicillin-clavulanate therapy (three patients), but not significantly so (P = 0.197). Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0.052). Gastrointestinal side effects occurred in 13 loracarbef-treated and 21 amoxicillin-clavulanate-treated patients (P = 0.13). Diaper rash was more common with amoxicillin-clavulanate (22 patients) than with loracarbef (10 patients; P = 0.016). Satisfactory results were achieved with both antibiotics, and adverse effects, although common, were minor.

UR - http://www.scopus.com/inward/record.url?scp=0025893718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025893718&partnerID=8YFLogxK

M3 - Article

C2 - 1854178

AN - SCOPUS:0025893718

VL - 35

SP - 967

EP - 971

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -